Literature DB >> 7678816

Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia.

M L Patchen1, R Fischer, T J MacVittie.   

Abstract

Hemopoietic aplasia is the primary limitation of drug and radiation cancer therapies. We have previously demonstrated that, individually, both interleukin-6 (IL-6) and granulocyte colony-stimulating factor (G-CSF) can accelerate recovery from radiation-induced hemopoietic aplasia. In vitro studies suggest that IL-6 affects cells early in the hemopoietic hierarchy, while G-CSF affects more committed progenitor cells. Because these cytokines may also affect different cell populations in vivo, we hypothesized that the use of these agents in combination may further enhance recovery from hemopoietic aplasia. Female B6D2F1 mice were exposed to a high sublethal 7.75 Gy dose of 60Co radiation. Following irradiation, mice were administered subcutaneous injections of either saline, 500 micrograms/kg of recombinant human IL-6 once daily on days 1-6, 125 micrograms/kg of recombinant human G-CSF once daily on days 1-17, or both cytokines as described. Peripheral white blood cell (WBC), red blood cell (RBC), and platelet (PLT) counts, as well as femoral and splenic granulocyte-macrophage colony-forming cell (GM-CFC) and day-12 spleen colony-forming unit (CFU-S) contents were evaluated on days 7, 10, 14, 17 and 21 postirradiation. IL-6 treatment alone slightly accelerated postirradiation recovery of most hemopoietic parameters, while G-CSF treatment dramatically enhanced recovery of all hemopoietic parameters evaluated. Co-administration of IL-6 and G-CSF further enhanced the hemopoietic recovery. The most notable effects in combination-treated mice were on recoveries of bone marrow and splenic CFU-S, which were significantly enhanced above those in G-CSF-treated irradiated mice as early as day 10 postirradiation. Although by day 14 postirradiation, splenic GM-CFC and CFU-S recoveries in both G-CSF- and combination-treated mice had surpassed unirradiated control values, combination-treated mice exhibited a greater overshoot. These studies demonstrate the ability of IL-6 treatment to enhance G-CSF-mediated acceleration of multilineage recovery following radiation-induced hemopoietic aplasia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678816

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  12 in total

1.  rBPI21 (Opebacan) Promotes Rapid Trilineage Hematopoietic Recovery in a Murine Model of High-Dose Total Body Irradiation.

Authors:  Kenneth J Janec; Huaiping Yuan; James E Norton; Rowan H Kelner; Christian K Hirt; Rebecca A Betensky; Eva C Guinan
Journal:  Am J Hematol       Date:  2018-05-11       Impact factor: 10.047

2.  Total Body Irradiation in the "Hematopoietic" Dose Range Induces Substantial Intestinal Injury in Non-Human Primates.

Authors:  Junru Wang; Lijian Shao; Howard P Hendrickson; Liya Liu; Jianhui Chang; Yi Luo; John Seng; Mylene Pouliot; Simon Authier; Daohong Zhou; William Allaben; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2015-10-23       Impact factor: 2.841

3.  Adverse effects of pefloxacin in irradiated C3H/HeN mice: correction with glucan therapy.

Authors:  M L Patchen; I Brook; T B Elliott; W E Jackson
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure.

Authors:  Vadim I Krivokrysenko; Alexander N Shakhov; Vijay K Singh; Frederick Bone; Yevgeniy Kononov; Inna Shyshynova; Alec Cheney; Ratan K Maitra; Andrei Purmal; Mark H Whitnall; Andrei V Gudkov; Elena Feinstein
Journal:  J Pharmacol Exp Ther       Date:  2012-07-26       Impact factor: 4.030

5.  Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.

Authors:  Lyudmila G Burdelya; Craig M Brackett; Bojidar Kojouharov; Ilya I Gitlin; Katerina I Leonova; Anatoli S Gleiberman; Semra Aygun-Sunar; Jean Veith; Christopher Johnson; Gary J Haderski; Patricia Stanhope-Baker; Shyam Allamaneni; Joseph Skitzki; Ming Zeng; Elena Martsen; Alexander Medvedev; Dmitry Scheblyakov; Nataliya M Artemicheva; Denis Y Logunov; Alexander L Gintsburg; Boris S Naroditsky; Sergei S Makarov; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

6.  The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent.

Authors:  Ann M Farese; Cassandra R Brown; Cassandra P Smith; Allison M Gibbs; Barry P Katz; Cynthia S Johnson; Karl L Prado; Thomas J MacVittie
Journal:  Health Phys       Date:  2014-01       Impact factor: 1.316

7.  Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.

Authors:  Hui Lin Chua; P Artur Plett; Carol H Sampson; Barry P Katz; Gilbert W Carnathan; Thomas J MacVittie; Keith Lenden; Christie M Orschell
Journal:  Health Phys       Date:  2014-01       Impact factor: 1.316

8.  Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome.

Authors:  Andrea M Patterson; Tong Wu; Hui Lin Chua; Carol H Sampson; Alexa Fisher; Pratibha Singh; Theresa A Guise; Hailin Feng; Jessica Muldoon; Laura Wright; P Artur Plett; Louis M Pelus; Christie M Orschell
Journal:  Radiat Res       Date:  2021-02-01       Impact factor: 2.841

Review 9.  Endothelial perturbations and therapeutic strategies in normal tissue radiation damage.

Authors:  Elina Korpela; Stanley K Liu
Journal:  Radiat Oncol       Date:  2014-12-18       Impact factor: 3.481

10.  The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.

Authors:  Vadim I Krivokrysenko; Ilia A Toshkov; Anatoli S Gleiberman; Peter Krasnov; Inna Shyshynova; Ivan Bespalov; Ratan K Maitra; Natalya V Narizhneva; Vijay K Singh; Mark H Whitnall; Andrei A Purmal; Alexander N Shakhov; Andrei V Gudkov; Elena Feinstein
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.